tradingkey.logo

Tivic Health Systems Inc

TIVC
1.890USD
0.000
收盤 12/24, 13:00美東報價延遲15分鐘
3.14M總市值
虧損本益比TTM

Tivic Health Systems Inc

1.890
0.000

關於 Tivic Health Systems Inc 公司

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

Tivic Health Systems Inc簡介

公司代碼TIVC
公司名稱Tivic Health Systems Inc
上市日期Nov 11, 2021
CEOErnst (Jennifer)
員工數量7
證券類型Ordinary Share
年結日Nov 11
公司地址47685 Lakeview Blvd
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94538
電話18882766888
網址https://tivichealth.com/
公司代碼TIVC
上市日期Nov 11, 2021
CEOErnst (Jennifer)

Tivic Health Systems Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月24日 週三
更新時間: 12月24日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
其他
82.71%
持股股東
持股股東
佔比
Avenue Capital Group
5.76%
Statera BioPharma, Inc
3.47%
DRW Securities, LLC
3.05%
Avenue Venture Opportunities Fund LP
2.84%
Marex Group plc
2.17%
其他
82.71%
股東類型
持股股東
佔比
Corporation
6.30%
Investment Advisor/Hedge Fund
6.04%
Investment Advisor
5.38%
Individual Investor
1.37%
Research Firm
0.08%
其他
80.82%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
2023Q2
33
60.32K
19.16%
+13.93K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Statera BioPharma, Inc
61.20K
3.89%
+61.20K
--
May 14, 2025
Avenue Venture Opportunities Fund LP
50.13K
3.18%
+50.13K
--
May 14, 2025
Marex Group plc
39.28K
2.5%
+39.28K
--
Jun 30, 2025
Ernst (Jennifer)
23.25K
1.48%
+22.54K
+3192.78%
Sep 22, 2025
Geode Capital Management, L.L.C.
--
0%
-2.15K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
5.65K
0.36%
+5.65K
--
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
公告日期
類型
比率
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1

常見問題

Tivic Health Systems Inc的前五大股東是誰?

Tivic Health Systems Inc的前五大股東如下:
Statera BioPharma, Inc
持有股份:61.20K
佔總股份比例:3.89%。
Avenue Venture Opportunities Fund LP
持有股份:50.13K
佔總股份比例:3.18%。
Marex Group plc
持有股份:39.28K
佔總股份比例:2.50%。
Ernst (Jennifer)
持有股份:23.25K
佔總股份比例:1.48%。
Geode Capital Management, L.L.C.
持有股份:0.00
佔總股份比例:0.00%。

Tivic Health Systems Inc的前三大股東類型是什麼?

Tivic Health Systems Inc 的前三大股東類型分別是:
Avenue Capital Group
Statera BioPharma, Inc
DRW Securities, LLC

有多少機構持有Tivic Health Systems Inc(TIVC)的股份?

截至2025Q3,共有22家機構持有Tivic Health Systems Inc的股份,合計持有的股份價值約為44.96K,占公司總股份的2.86% 。與2025Q2相比,機構持股有所增加,增幅為-7.96%。

哪個業務部門對Tivic Health Systems Inc的收入貢獻最大?

在--,--業務部門對Tivic Health Systems Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI